Top-down therapy for IBD: rationale and requisite evidence.
about
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsMucosal healing and deep remission: what does it mean?Use of the tumor necrosis factor-blockers for Crohn's diseaseClinical and genetic factors predicting response to therapy in patients with Crohn's disease.Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.Current and future role of biomarkers in Crohn's disease risk assessment and treatment.Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.Biologics in paediatric Crohn's disease.Select a suitable treatment strategy for Crohn's disease: step-up or top-down.The PIRO (predisposition, insult, response, organ dysfunction) model: toward a staging system for acute illness.When combination therapy isn't working: emerging therapies for the management of inflammatory bowel diseaseOptimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes.Review article: breath analysis in inflammatory bowel diseases.Systematic review: Whipple's disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors.Implementing quality measures for inflammatory bowel disease.Oral Manifestations of Crohn's Disease: A Case Report and Review of the LiteratureMultifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis.Disseminated Tuberculosis in a Patient Taking Anti-TNF Therapy for Crohn's Disease.Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis.The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease.Human herpes virus-6 chromosomal integration misled the management of Crohn's disease.Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.Psoriasis concurrent with inflammatory bowel disease.Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery.Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease.RDW as a Surrogate Marker for Active Crohn's Disease: Potential Utility.
P2860
Q26768280-1999704E-C51D-4FE0-B230-8D45A800E5AAQ26852447-476ACBA6-0E4B-48F0-B4D0-53A505527E61Q27030762-C485DE0F-8D25-40FF-AC75-6265463D331BQ33695605-6B9DD5FD-0AF6-491F-AC08-DCF39D631B01Q34367007-31BEF47F-2F33-4562-9BB7-850C5A932DDEQ35095265-F6BFEF65-D66A-4213-93D8-32EECAD68202Q35381299-0E89663A-4CFB-40F1-B123-D467694049FCQ35579308-FD58BDE5-7A52-472E-B8B5-AAEA4A4DF367Q35721537-71BE111B-07EC-4544-8037-E8E2D47E4EC4Q37563016-D9C50ABB-ECD9-47BE-830C-D9A868024101Q37578631-D010D7BA-352A-455C-9615-0754F6C31317Q37947158-A1608BE0-9851-4222-A194-1960D21B24BFQ38185950-54DD6BF3-F0F4-4311-9D66-E4C54919BB71Q38293574-6C834E11-1FEF-4403-A750-A682A588E53FQ38360672-B19CE010-0ABE-4597-820A-4189D086A4E4Q38374554-C1A03501-05DF-42E1-BB6C-8396F1C90FABQ38560433-F782F869-9950-45ED-A29B-C8778EE5497DQ39001317-33B8F7B4-FEAF-4A8E-BF11-74685343060EQ40133824-F24CCF20-59C9-4003-B592-893B3856F63DQ40266793-2C154515-942C-473C-BCE8-BBDC0E38E8BCQ40327479-177E3A90-C093-4F18-BAC0-89F34528C896Q40382305-ACD946D1-43B4-4DAD-B06D-0ABE21F649EFQ44209841-4A658AB4-4A6E-4096-88B8-FB73D5BF529BQ45365924-FF6AD485-3018-4375-A134-A2AD74608048Q47990338-86887B54-5BD9-48B4-A311-54A87B6E34FEQ50602849-9B464C0E-1391-4BD9-A1F6-74A43EFF56E9Q51412257-648B1538-4DC6-4126-978A-A5045F9F3B9FQ53170686-89AFB73E-6E3C-4DB5-A49E-F4C77674A339Q54241552-B6AC0CCC-9D83-4DD8-9977-B6F6397B9C7C
P2860
Top-down therapy for IBD: rationale and requisite evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Top-down therapy for IBD: rationale and requisite evidence.
@en
Top-down therapy for IBD: rationale and requisite evidence.
@nl
type
label
Top-down therapy for IBD: rationale and requisite evidence.
@en
Top-down therapy for IBD: rationale and requisite evidence.
@nl
prefLabel
Top-down therapy for IBD: rationale and requisite evidence.
@en
Top-down therapy for IBD: rationale and requisite evidence.
@nl
P2860
P1476
Top-down therapy for IBD: rationale and requisite evidence.
@en
P2093
Geert R D'Haens
P2860
P2888
P356
10.1038/NRGASTRO.2009.222
P407
P577
2010-02-01T00:00:00Z